Allogeneic hematopoietic stem cell transplantation is a life-saving procedure for patients with various hematologic malignancies and disorders. Despite its clinical benefits, allo-HSCT is associated with significant economic burdens, including high upfront costs, long-term healthcare utilization and indirect costs related to productivity losses. This economic analysis aims to evaluate the costs and cost-effectiveness of allo-HSCT from both healthcare system and societal perspectives. From the healthcare system perspective, direct medical costs include pre-transplantation workup, hospitalization costs, physician fees, medication expenses and post-transplantation care. Additionally, indirect costs such as complications, readmissions and supportive care contribute to the economic burden. Furthermore, the advent of novel technologies, such as reduced-intensity conditioning regimens and haploidentical transplantation, has introduced additional cost considerations. From a societal standpoint, the economic impact extends beyond healthcare expenditures to include productivity losses due to patient and caregiver time away from work, as well as the long-term implications of transplant-related complications on quality of life and functional status. This analysis will review existing literature on the economic aspects of allo-HSCT, including cost-effectiveness studies, budget impact analyses and reimbursement policies. Furthermore, it will highlight areas for future research to optimize resource allocation and improve patient outcomes while containing costs. Understanding the economic implications of allo-HSCT is crucial for healthcare policymakers, payers and providers to make informed decisions regarding resource allocation and reimbursement strategies in this rapidly evolving field.
HTML PDFShare this article
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report
